Our study supports the importance of genetic testing to detect patients who could benefit from molecular diagnostics, genetic counseling, and specific medical management, such as setmelanotide, that has been tested as a specific anti-obesity drug to treat obese subjects with MC4R polymorphism, evading adverse effects, which are related to other pharmacological treatments. This evidence concerns the gene MC4R and Obesity.